Premium
Is elimination of HCV in 2030 realistic in Central Europe
Author(s) -
Flisiak Robert,
ZarębskaMichaluk Dorota,
Frankova Sona,
Grgurevic Ivica,
Hunyady Bela,
Jarcuska Peter,
Kupčinskas Limas,
Makara Michael,
Simonova Marieta,
Sperl Jan,
Tolmane Ieva,
Vince Adriana
Publication year - 2021
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/liv.14834
Subject(s) - medicine , regimen , covid-19 , european region , hepatitis c , virology , environmental health , geography , regional science , disease , infectious disease (medical specialty)
According to the recent data presented by Central‐European HCV experts, the estimated prevalence of HCV is between 0.2% and 1.7% in certain countries in this region. There are no financial limitations to access to treatment in most countries. Patients in these countries have access to at least one pangenotypic regimen. The most common barriers to the elimination of HCV in Central Europe are a lack of established national screening programmes and limited political commitment to the elimination of HCV. Covid‐19 has significantly affected the number of patients who have been diagnosed and treated, thus, delaying the potential elimination of HCV. These data suggest that the elimination of HCV elimination projected by WHO before 2030 will not be possible in the Central Europe.